General Comments / Chat, page-8672

HeyLine thanks for the positive vibes, glad that I can contribute from time to time in my limited capacity. A lot of what I share came about from DYOR after other spotted something I didn’t understand, @Davisite video interviews & going further to gain basic understanding of Mason’s FTO expiation etc. One thing that helped me was actually doing an online course for Drug Project management that covered drug discovery, drug development & drug commercialisation.

This is where I am seeing the dots connect as now I am seeing the RAC conversation cover the commercialisation part of the course. Well worth spending some money to do a course instead of me chucking money at something I don’t understand enough.

Any how let me try to answer from my point of view.

1. Above my pay grade & experience, however given current MC we need to have some pivots & pass our ATH to start with. Others have pointed out market in general, economy & biotech as a whole but once we have some solid turning points I expect several rerates as alliances, partnerships develop as well as drug development requirements such as FDA approvals.
2. DCB mentioned partnerships, licences, M&A. Any of these will de-risk & usually make market notice. If a BP came along & announced they were partnering with us (check the M&A slide photo I included) in some form it often leads to institutional investors taking notice. As we know few of them have taken the time to understand what biotechs offer in depth, so seeing a BP involved will turn heads.
3. Depends on what form the partnership takes. They need to be win win for both parties & I am expecting small plays at first. We have already had several that haven’t fully branched out that we are aware, but COH is a great example that is now back where we wanted it some time ago, but had been delayed for a variety of reasons. Having control over our IP should have seen our MC much higher alone. Again partnerships can take many forms.
4. I’m waiting on the August update as I think this will answer a lot of questions, at least we know where we stand with the fielding of questions & approaches to BP to add to their businesses & pipelines. If you were a BP executive you would not commit millions of $ & risk your own career, company SP unless you had a lot of data to back up the claims of a biotech drug. We are on many radars & once more data from drug development (trials) comes along will be wanted by BP. That being said our data to date, amazing cardio protective discoveries & potential to change cancer treatment would be reason enough for an early partnership that would see higher SP. Doesn’t need to give away equity could be a revenue % like COH agreement.
5. Depends on the M&A. Ranking I am looking for are: Informal collaboration, contractual agreements, non-equity alliances (joint R&D, joint product development/manufacturing/marketing, long-term sourcing agreements), equity alliance, joint venture, M&A. Think of the access to resources RAC would get working with any BP. From R&D datasets to clinicians, patients, sales team, marketing, manufacturing your name it. Impossible fro RAC to grow a team that can handle all of that especially in competition.
6. Frustrating isn’t it. Friends and family probably hassling all of us that recommend they all DYOR on RAC right. As I see it personally I feel I’ve bought into PLS back at 27c (I had a but at 25c that I missed cause PLS went to 27, chickened out cause I didn’t understand the stock, then missed out on an 18 bagger.). People that have made big returns tell me that their understanding of the company, the leadership, product, the space company is in rather than looking at a ticker & charts is what saw them big returns over the long term. I go back from time to time to rewatch the interviews & reread the papers as my own understanding improves & I find I pick something up each time. In terms of drug pharmacoeconomics the Triangle report was the one that fleshed everything out to me as they really explain how & why they valued it how they did & why so conservative. Kind of like Amazon saying 3-5 day delivery & arriving in 2.

To summarise I am eagerly awaiting the update in August, but encourage people do not expect us to suddenly have a $21B offer announced right then & there. Tiered steps to get to that point is a possibility & I will be jumping for joy when some form happens & to start with I am in the green. Until then I am continuing to bring down my average which was once above $4, mostly in high $3, but now about $2.60.

Lastly biotech takes time. RAC is an exciting company, but with so many parts moving during this new phase DCB is talking about that I encourage all to take some time away, ignore the noise, ignore the urge to get that dopamine hit & just wait for an announcement.

How many times have we all worked ourselves up with wild speculation that is usually way off of the mark? RAC threads have to be the best on HC I’ve visited & looking forward to the day when we can all celebrate a massive win.